Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Sesen Bio, Inc.
Sesen Bio Stockholders Approve Merger with Carisma Therapeutics
March 02, 2023
From
Sesen Bio, Inc.
Via
Business Wire
Tickers
SESN
Sesen Bio Reports Fourth Quarter and Full-Year 2022 Financial Results
February 28, 2023
From
Sesen Bio, Inc.
Via
Business Wire
Tickers
SESN
Leading Independent Proxy Advisory Firm Glass Lewis Joins ISS in Recommending That Sesen Bio Stockholders Vote “FOR” All Proposals to Approve Pending Merger With Carisma
February 21, 2023
From
Sesen Bio, Inc.
Via
Business Wire
Tickers
SESN
Leading Independent Proxy Advisory Firm ISS Recommends Sesen Bio Stockholders Vote “FOR” All Proposals at March 2 Special Meeting
February 16, 2023
From
Sesen Bio, Inc.
Via
Business Wire
Tickers
SESN
Sesen Bio to Host Webcast with Carisma Therapeutics to Discuss Pending Merger
February 16, 2023
From
Sesen Bio, Inc.
Via
Business Wire
Tickers
SESN
BML, One of Sesen Bio’s Top Stockholders, Announces Support for Pending Merger with Carisma Therapeutics
February 15, 2023
From
Sesen Bio, Inc.
Via
Business Wire
Tickers
SESN
Sesen Bio and Carisma Therapeutics Announce Increased Special Cash Dividend and Stockholder Support for Pending Merger
February 14, 2023
From
Sesen Bio, Inc.
Via
Business Wire
Tickers
SESN
Sesen Bio Files Investor Presentation in Connection with Pending Carisma Therapeutics Merger
February 02, 2023
From
Sesen Bio, Inc.
Via
Business Wire
Tickers
SESN
Sesen Bio Receives NASDAQ Delisting Notice
January 30, 2023
From
Sesen Bio, Inc.
Via
Business Wire
Tickers
SESN
Sesen Bio Reiterates Confidence that Pending Merger with Carisma is in Best Interests of Stockholders
January 26, 2023
From
Sesen Bio, Inc.
Via
Business Wire
Tickers
SESN
Sesen Bio Files Definitive Proxy Statement and Mails Letter to Stockholders in Connection with Pending Merger with Carisma Therapeutics
January 19, 2023
From
Sesen Bio, Inc.
Via
Business Wire
Tickers
SESN
Sesen Bio Reiterates Confidence in Pending Merger with Carisma Therapeutics
January 04, 2023
From
Sesen Bio, Inc.
Via
Business Wire
Tickers
SESN
Sesen Bio and Carisma Therapeutics Announce Substantial Increase to Expected Special Cash Dividend in Connection with Pending Merger
December 29, 2022
From
Sesen Bio, Inc.
Via
Business Wire
Tickers
SESN
Sesen Bio and Carisma Therapeutics Announce Merger Agreement
September 21, 2022
From
Sesen Bio, Inc.
Via
Business Wire
Tickers
SESN
Sesen Bio Announces Anticipated Regulatory Path Forward for Vicineum™
December 09, 2021
From
Sesen Bio, Inc.
Via
Business Wire
Tickers
SESN
Sesen Bio Strengthens Leadership Team as the Company Approaches the Potential Approval and Launch of Vicineum™
August 02, 2021
From
Sesen Bio, Inc.
Via
Business Wire
Tickers
SESN
Sesen Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
June 18, 2021
From
Sesen Bio, Inc.
Via
Business Wire
Tickers
SESN
Dr. Thomas Cannell, President and CEO of Sesen Bio, to Participate in Fireside Chat at the 2021 Jefferies Virtual Healthcare Conference
May 27, 2021
From
Sesen Bio, Inc.
Via
Business Wire
Tickers
SESN
Dr. Thomas Cannell, President and CEO of Sesen Bio, and Dr. Michael Jewett, FRCSC, FACS, to Participate in Canaccord Genuity “Horizons in Oncology” Virtual Conference
April 08, 2021
From
Sesen Bio, Inc.
Via
Business Wire
Tickers
SESN
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit